Amgen at neutral by Merrill

Merrill Lynch analyst Eric Ende gave Amgen Inc. a neutral rating. At the Merrill Lynch conference, following Roche's presentation, Amgen stated that it is confident that Mircera infringes its EPO patent franchise. It was determine that Roche's statements were the clearest to date about its launch readiness. Shares of the Thousand Oaks, Calif.-based biotechnology company were down $1.12, or 1.56%, at $70.89. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.